drugset / Trial / NCT00809588
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)
Phase 1
Completed
84 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the proposed therapy will delay or stop the progression of the participants skin cancer. This study is being done because there are currently no treatments which have been shown convincing to treat disease which has progressed. This research study is designed to evaluate the immunologic effects and clinical side effects of giving vaccines to patients that are made from their own skin cancer cells.
Timeline
- Start
- 2003-10-16
- Primary completion
- 2016-09
- Completion
- 2020-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous, lethally irradiated melanoma cells | Vaccine | — | Subcutaneous |